Skip to main content
OpenTrials

Clinical trial condition

Metastatic Breast Cancer

Explore clinical trials studying Metastatic Breast Cancer. Study availability and eligibility vary by location and protocol.

640 public trials 137 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Breast Cancer trial results

Completed

BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer

NCT02783794

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +5 more
Locations
  • Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS) Moscow, Russia
  • State Budgetary Institution of Nizhniy Novgorod Region "Oncology Dispensary of Nizhniy Novgorod" (Branch nr.1) Nizhny Novgorod, Russia
  • Leningrad Regional Oncological Centre Saint Petersburg, Russia
  • St. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary Saint Petersburg, Russia
View Trial Details
Completed

BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment

NCT03789019

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +5 more
Locations
  • Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS) Moscow, Russia
  • Leningrad Regional Oncological Centre Saint Petersburg, Russia
  • St. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary Saint Petersburg, Russia
  • Siriraj Hospital, Mahidol University Bangkok, Thailand
View Trial Details
Completed

A Study of LY2523355 in Participants With Breast Cancer

NCT01416389

Conditions
Breast Diseases, Breast Neoplasms, Disease Attributes, +8 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fort Myers, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Pensacola, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gainesville, Georgia, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bethesda, Maryland, United States
View Trial Details
Completed

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

NCT00274469

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +4 more
Locations
  • Research Site Frederick, Maryland, United States
  • Research Site St Louis, Missouri, United States
  • Research Site Teaneck, New Jersey, United States
  • Research Site Austin, Texas, United States
View all 41 locations
View Trial Details
Completed

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

NCT03007992

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +4 more
Locations
  • Universitätsklinikum Düsseldorf, Frauenklinik Düsseldorf, Germany
  • Klinikum Frankfurt-Höchst Klinik für Gynäkologie und Geburtshilfe - Operative und konservative Gynäkologie, Gynäkologische Onkologie, Pränataldiagnostik, Geburtshilfe Frankfurt am Main, Germany
  • Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Gynäkologie Halle, Germany
  • Onkologische Schwerpunktpraxis Dr. Karcher, Dr. Fuxius, Dr. Debatin Heidelberg, Germany
View Trial Details

Related conditions